StockData
Matinas BioPharma Holdings, Inc. logo

Matinas BioPharma Holdings, Inc. (MTNB) stock

MTNBNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 0/30
$0.91+0.05 (+6.35%)

Close on Nov 18, 2026Market cap $13.37MP/E –Yield –

Matinas BioPharma total assets

Total assets on the balance sheet at the end of each period.

Matinas BioPharma's total assets was $3.41M at Jun 30, 2026. For fiscal 2025 it was $7.21M, down 43.0% from the year before. Over ten years it grew -1.5% a year on average. The highest annual figure on record is $70.97M in fiscal 2020.

Annual total assets

PeriodPeriod endValueChange
FY2025Dec 31, 2025$7.21M-43.0%
FY2024Dec 31, 2024$12.64M-49.6%
FY2023Dec 31, 2023$25.10M-44.0%
FY2022Dec 31, 2022$44.82M-26.9%
FY2021Dec 31, 2021$61.33M-13.6%
FY2020Dec 31, 2020$70.97M+76.4%
FY2019Dec 31, 2019$40.24M+101.8%
FY2018Dec 31, 2018$19.94M+38.3%
FY2017Dec 31, 2017$14.42M+46.9%
FY2016Dec 31, 2016$9.82M+16.8%
FY2015Dec 31, 2015$8.41M+150.1%
FY2014Dec 31, 2014$3.36M-70.3%
FY2013Dec 31, 2013$11.33M–

Quarterly total assets

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$3.41M-70.1%
Q1 FY2026Mar 31, 2026$5.87M-51.2%
Q4 FY2025Dec 31, 2025$7.21M-43.0%
Q3 FY2025Sep 30, 2025$9.70M-52.9%
Q2 FY2025Jun 30, 2025$11.42M-53.1%
Q1 FY2025Mar 31, 2025$12.04M-38.6%
Q4 FY2024Dec 31, 2024$12.64M-49.6%
Q3 FY2024Sep 30, 2024$20.58M-30.9%
Q2 FY2024Jun 30, 2024$24.37M-28.4%
Q1 FY2024Mar 31, 2024$19.61M-48.7%
Q4 FY2023Dec 31, 2023$25.10M-44.0%
Q3 FY2023Sep 30, 2023$29.79M-37.3%
Q2 FY2023Jun 30, 2023$34.03M-35.1%
Q1 FY2023Mar 31, 2023$38.26M-31.4%
Q4 FY2022Dec 31, 2022$44.82M-26.9%
Q3 FY2022Sep 30, 2022$47.55M-29.0%
Q2 FY2022Jun 30, 2022$52.42M-25.1%
Q1 FY2022Mar 31, 2022$55.78M-22.9%
Q4 FY2021Dec 31, 2021$61.33M-13.6%
Q3 FY2021Sep 30, 2021$66.98M-10.5%
Q2 FY2021Jun 30, 2021$69.97M-11.5%
Q1 FY2021Mar 31, 2021$72.35M-14.0%
Q4 FY2020Dec 31, 2020$70.97M+76.4%
Q3 FY2020Sep 30, 2020$74.81M+66.9%
Q2 FY2020Jun 30, 2020$79.09M+64.0%
Q1 FY2020Mar 31, 2020$84.11M+66.3%
Q4 FY2019Dec 31, 2019$40.24M+101.8%
Q3 FY2019Sep 30, 2019$44.82M+211.0%
Q2 FY2019Jun 30, 2019$48.21M+200.5%
Q1 FY2019Mar 31, 2019$50.57M+340.2%
Q4 FY2018Dec 31, 2018$19.94M+38.3%
Q3 FY2018Sep 30, 2018$14.41M-12.8%
Q2 FY2018Jun 30, 2018$16.04M-9.9%
Q1 FY2018Mar 31, 2018$11.49M-47.9%
Q4 FY2017Dec 31, 2017$14.42M+46.9%
Q3 FY2017Sep 30, 2017$16.52M+46.1%
Q2 FY2017Jun 30, 2017$17.80M–
Q1 FY2017Mar 31, 2017$22.03M–
Q4 FY2016Dec 31, 2016$9.82M–
Q3 FY2016Sep 30, 2016$11.31M–

More Matinas BioPharma figures

See a number that looks wrong?